---
title: 'Clinical practice recommendations on lipoprotein apheresis for children with
  homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet
  and ESPN'
date: '2024-04-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38598969/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240411180910&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Homozygous familial hypercholesterolaemia is a life-threatening genetic
  condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular
  disease very early in life. It is vital to start effective lipid-lowering treatment
  from diagnosis onwards. Even with dietary and current multimodal pharmaceutical
  lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children.
  Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is used
  ...
disable_comments: true
---
Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children. Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is used ...